ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Registration Strip Icon for alerts Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
Amarantus Bioscience Holdings Inc (CE)

Amarantus Bioscience Holdings Inc (CE) (AMBS)

0,0001
0,00
(0,00%)
Geschlossen 02 November 9:00PM

Ihr Hub für Echtzeit-Streaming-Zitate, Ideen und Live-Diskussionen

Wichtige Statistiken und Details

Current Price
0,0001
Gebot
0,00
Fragen
0,00
Volumen
-
0,00 Tagesbereich 0,00
0,000001 52-Wochen-Bereich 0,0401
Marktkapitalisierung
Handelsende
0,0001
Handelsbeginn
-
Letzte Trade
Letzter Handelszeitpunkt
Finanzvolumen
-
VWAP
-
Durchschnittliches Volumen (3 Mio.)
131.630
Ausgegebene Aktien
68.272.000
Dividendenrendite
-
Kurs-Gewinn-Verhältnis
0,00
Gewinn pro Aktie (EPS)
-0,07
Erlöse
95k
Nettogewinn
-4,76M

Über Amarantus Bioscience Holdings Inc (CE)

Amarantus Bioscience Holdings (AMBS) is a biotechnology company developing treatments and diagnostics for diseases in the areas of neurology, regenerative medicine and orphan diseases through its subsidiaries. AMBS acquired the rights to the Engineered Skin Substitute program (ESS), a regenerative m... Amarantus Bioscience Holdings (AMBS) is a biotechnology company developing treatments and diagnostics for diseases in the areas of neurology, regenerative medicine and orphan diseases through its subsidiaries. AMBS acquired the rights to the Engineered Skin Substitute program (ESS), a regenerative medicine-based approach for treating severe burns with full-thickness autologous skin grown in tissue culture that is being pursued by AMBS' wholly-owned subsidiary Cutanogen Corporation. AMBS' wholly-owned subsidiary MANF Therapeutics, Inc. owns key intellectual property rights and licenses from a number of prominent universities related to the development of the therapeutic protein known as mesencephalic astrocyte-derived neurotrophic factor ("MANF"). MANF Therapeutics, Inc. is developing MANF-based products as treatments for brain and ophthalmic disorders. MANF was discovered by the Company's Chief Scientific Officer John Commissiong, PhD. Dr. Commissiong discovered MANF from AMBS' proprietary discovery engine PhenoGuard. AMBS sold subsidiary Breakthrough Diagnostics to Todos Medical Ltd. in July of 2020. The Company also owns 51% of hemp/CBD company Hempori. Mehr anzeigen

Sektor
Pharmaceutical Preparations
Branche
Pharmaceutical Preparations
Hauptsitz
Carson City, Nevada, USA
Gegründet
-
Amarantus Bioscience Holdings Inc (CE) is listed in the Pharmaceutical Preparations sector of the OTCMarkets with ticker AMBS. The last closing price for Amarantus Bioscience (CE) was US$0,00. Over the last year, Amarantus Bioscience (CE) shares have traded in a share price range of US$ 0,000001 to US$ 0,0401.

Amarantus Bioscience (CE) currently has 68.272.000 shares in issue. The market capitalisation of Amarantus Bioscience (CE) is US$6.827,20 . Amarantus Bioscience (CE) has a price to earnings ratio (PE ratio) of 0.00.

AMBS Neueste Nachrichten

Todos Medical Expands Extraction Reagent and ANDiS 350 Extraction Automation Capacity to Support COVID-19 Testing in the USA

Full US use of ANDiS 350 extraction systems would increase US daily testing capacity by 25% 3D Med extraction capacity increased by 1,000,000 kits per week Extraction reagent and automation...

Amarantus Acquires Majority Interest in CBD Wellness Company Hempori

Amarantus Acquires Majority Interest in CBD Wellness Company Hempori    Strong customer retention at both stores in Dallas, TX with growing online presence  Focus...

Amarantus Provides 2019 Roadmap

  Amarantus Provides 2019 Roadmap   New York, NY -- January 7, 2019 -- InvestorsHub NewsWire -- Amarantus Bioscience Holdings, Inc. (OTC Pink: AMBS) (the...

Coeptis Pharma Enters into Agreement to Acquire Elto Pharma

    Coeptis Pharma Enters into Agreement to Acquire Elto Pharma   New York, NY and Wexford, PA -- November 28, 2018 -- InvestorsHub NewsWire -- Coeptis...

Amarantus Provides Corporate Update

  Amarantus Provides Corporate Update   New York, NY -- July 20, 2018 -- InvestorsHub NewsWire -- Amarantus Bioscience Holdings, Inc. (OTC Pink: AMBS) (the...

MANF Therapeutics Announces Positive MANF Pre-Clinical Data in Alpha-Synuclein Model of Parkinson's Disease Published in

  MANF Therapeutics Announces Positive MANF Pre-Clinical Data in Alpha-Synuclein Model of Parkinson's Disease Published in Peer-Reviewed Journal Experimental...

MANF Therapeutics Announces Independent Publication of Positive Data for MANF in Traumatic Brain Injury Animal Model

  MANF Therapeutics Announces Independent Publication of Positive Data for MANF in Traumatic Brain Injury Animal Model New York, NY -- June 11, 2018 -- InvestorsHub NewsWire...

Amarantus Provides Update on Elto Pharma Capital Formation Plan

  Amarantus Provides Update on Elto Pharma Capital Formation Plan   New York, NY -- June 07, 2018 -- InvestorsHub NewsWire --  Amarantus Bioscience Holdings, Inc...

MANF Therapeutics Announces Publication of Positive Data for MANF in Stroke Animal Model in AAAS Journal Science Advances

  MANF Therapeutics Announces Publication of Positive Data for MANF in Stroke Animal Model in AAAS Journal Science Advances   New York, NY USA -- June 05, 2018...

Amarantus Exercises Exclusive Option with Leipzig University for Alzheimer's Blood Diagnostic "LymPro Test 2.0"

Amarantus Exercises Exclusive Option with Leipzig University for Alzheimer's Blood Diagnostic "LymPro Test 2.0"   Scope of exercised Exclusive Option Agreement...

Zeitraum †ÄnderungÄnderung %HandelsbeginnHochNiedrigDurchsch. VolumenVWAP
1000.00010.00010.000181690.0001CS
4-0.04-99.75062344140.04010.04011.0E-61912770.00020051CS
129.9E-599001.0E-60.04011.0E-61316300.00016407CS
26000.00010.04011.0E-6797090.0001501CS
52-0.0005-83.33333333330.00060.04011.0E-67448310.00092068CS
156-0.0065-98.48484848480.00660.04011.0E-617189480.00379027CS
260-0.0159-99.3750.0160.04011.0E-614353220.00598427CS
  • Volumen
  • % Tops
  • % Flops
SymbolPreisVol.
BLIAQBB Liquidating Inc (CE)
US$ 0,001
(99.900,00%)
102,03k
ERHEERHC Energy Inc (CE)
US$ 0,001
(99.900,00%)
5,11M
GAPJGolden Apple Oil and Gas Inc (CE)
US$ 0,001
(99.900,00%)
130
VIPZVIP Play Inc (PK)
US$ 0,75
(62.400,00%)
300
FFRMFFuture Farm Technologies Inc (CE)
US$ 0,000101
(10.000,00%)
1,25k
REPCFRepliCel Life Sciences Inc (CE)
US$ 0,000001
(-99,98%)
2,5k
AHPIQAllied Healthcare Products Inc (CE)
US$ 0,000001
(-99,50%)
1,16k
JUVAFJuva Life Inc (CE)
US$ 0,000001
(-99,00%)
300
DXBRFBellRock Brands Inc (CE)
US$ 0,000001
(-99,00%)
193,88k
MNGGMining Global Inc (PK)
US$ 0,000001
(-99,00%)
4,7M
NSAVNet Savings Link Inc (PK)
US$ 0,0006
(-68,42%)
1,1B
HMBLHUMBL Inc (PK)
US$ 0,0003
(50,00%)
260,3M
RDARRaadr Inc (PK)
US$ 0,001
(-9,09%)
214,52M
NNAXNew Momentum Corporation (PK)
US$ 0,0006
(0,00%)
194,37M
ASIIAccredited Solutions Inc (PK)
US$ 0,0009
(0,00%)
138,32M
Keine Diskussionen Gefunden.
Neuen Thread Erstellen

Kürzlich von Ihnen besucht

Delayed Upgrade Clock